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To the Editor: Recent reports from Asia (1–4) have 
highlighted the increasing incidence of the fungus Can-
dida auris as a nosocomial bloodstream pathogen affect-
ing persons of all age groups. We report a case of C. auris 
candidemia in a 27-year-old woman in Kuwait with a long 
history of chronic renal failure. On May 9, 2014, the pa-
tient was admitted to the intensive care unit with symptoms 
of septic shock secondary to lobar pneumonia and com-
plicated by acute renal failure. The patient was known to 
have immotile cilia syndrome (primary ciliary dyskinesia) 
and bronchiectasis with recurrent episodes of sinusitis. 
Beginning on day 1, she received treatment with different 
courses of a wide range of broad-spectrum antimicrobial 
drugs. However, despite treatment, the patient’s condi-
tion continued to deteriorate. On day 12 after admission, 
a blood culture yielded yeast growth that was identified 
with 99% probability as C. haemulonii by using the Vitek 
2 yeast identification system (bioMérieux, Marcy l’Etoile, 
France). As part of routine patient care, we sent the isolate 
(Kw1732/14) to the Mycology Reference Laboratory at 
Kuwait University for further identification and antifungal 
susceptibility testing. The isolate was resistant to flucon-
azole (MIC of >256 µg/mL), but it appeared susceptible to 
amphotericin B (MIC of 0.064 µg/mL), voriconazole (MIC 
of 0.38 µg/mL), and caspofungin (MIC of 0.064 µg/mL) by 
using the Etest (bioMérieux, Marcy l’Etoile, France). The 
patient was started on liposomal amphotericin B (150 mg/
day), but the next day, she died from multiorgan failure.
On MAST ID CHROMagar Candida medium (Mast 
Group Ltd., Bootle, UK), the isolate formed pink colonies, 
which grew well at 42°C but not at 45°C. The isolate did 
not grow on BBL Mycosel Agar (BD, Sparks, MD, USA) 
containing 0.4 g cycloheximide per liter of medium. As with 
C. auris isolates from India and South Africa, this isolate 
assimilated N-acetyl glucosamine (2,5). Because the iso-
late showed reduced susceptibility to fluconazole, it was 
further characterized by sequencing of internal transcribed 
spacer and D1/D2 domains of ribosomal DNA. Genomic 
sequences for the internal transcribed spacer and D1/D2 
regions (EMBL accession nos. LN624638 and LN626311) 
shared 99%–100% identity with sequences for correspond-
ing regions of several C. auris strains (identification nos. 
CBS12874, CBS12875, CBS12876, CBS12880, CBS12882, 
CBS12886, and CBS12887, and several isolates from India).
C. auris was isolated in 2009 from the ear canal of 
a woman in Japan (6). The species has attracted attention 
because of its reduced susceptibility to azoles and ampho-
tericin B (2,5) and its misidentification as C. haemulonii 
or Rhodotorula glutinis by commercial yeast identifica-
tion systems (1,4). Because there are no reliable pheno-
typic methods for the rapid identification of C. auris and 
because molecular methods are not yet widely available, it 
is reasonable to infer that C. auris may be a more frequent 
cause of candidemia than previously recognized, particu-
larly in Asian countries. A recently published multicenter 
study from India supports this view (7). In that study, a 
significantly higher occurrence of C. auris candidemia was 
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reported among patients admitted in public sector hospitals 
compared with those in private hospitals (8.2 vs. 3.9%; p = 
0.008) (7). The report reinforces the growing clinical impli-
cations of rare Candida spp. in the etiology of candidemia 
and highlights the role of molecular methods for their un-
equivocal identification.
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